Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring Mabwell marks a milestone with the first dosing in China of its innovative anti-IL-11 antibody, aiming to treat pathological scarring in a Phase II trial.

Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring #China #Shanghai #Mabwell #Anti-IL-11 #Pathological_Scarring